Radar · Neurology in California
Best Neurology Companies in California, United States
The 441 best Neurology companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Biosplice.
By Rohit KhannaTrends & Stories
441companies tracked
$14.1Bdisclosed funding
3unicorns
247have raised
FLIAR INTELLIGENCE · NEUROLOGY × CALIFORNIA
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
74%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
755kcombined LinkedIn audience
67%of audience held by top 3
5companies hiring publicly (12 mo)
Ranked: Best Neurology companies in California
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Neuralink 🦄 Provider of implantable brain-computer interfaces 78Funding top 15%Patents top 25%Moat top 25%Innovation top 27% All 10 signals ▾Fundingtop 15% Patentstop 25% Moattop 25% Innovationtop 27% Talenttop 28% Markettop 33% Growthtop 42% Techtop 44% Globalbottom 39% Newsbottom 24% Funding: Raised $680M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) Patents: 97 patents matched (strict assignee match) · 62 filings since 2022 vs 35 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $680M | 1 mo ago | 197 | Dongjin Seo Co-Founder | Apple iCloud MailGoogle WorkspaceGSAP+12 | 97 patents High‑density, biocompatible neural interface hardware and real‑time spike processing | 1 launch |
| 2 | Kriya Therapeutics Developer of therapeutic solutions for the treatment of diabetes 53Funding top 16%News top 24%Moat top 31%Growth top 43% All 8 signals ▾Fundingtop 16% Newstop 24% Moattop 31% Growthtop 43% Markettop 44% Talenttop 50% Globalbottom 37% Techbottom 32% Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $618M | 10 mo ago | 159 | Shankar Ramaswamy Co-Founder & CEO | WordPress Site EditorWordPressMySQL+12 | — | — |
| 3 | Denali Therapeutics Developer of therapies to treat neurodegenerative diseases | $347M | 27 mo ago | 377 377 → 582 (+54%) · sector median +50% | Alexander Schuth Co-Founder | WordPressApple iCloud MailTypeScript+24 | 1,002 patents Neurodegenerative antibody therapies and enzyme‑fusion biologics for lysosomal disease treatment | — |
| 4 | Neurona Therapeutics Developer of cell-based therapies to treat intractable neurological diseases 55Funding top 22%Moat top 31%Growth top 32%AI top 45% All 8 signals ▾Fundingtop 22% Moattop 31% Growthtop 32% AItop 45% Talentbottom 49% Marketbottom 43% Globalbottom 39% Techbottom 30% Funding: Raised $316M across 9 rounds · 9 rounds over 18 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 55/100 | $316M | 14 mo ago | 67 67 → 116 (+73%) · sector median +50% | Cory Nicholas CEO | Apple iCloud MailApache HTTP ServerMicrosoft Advertising+5 | — | 1 award |
| 5 | MapLight Developer of therapeutic for central nervous system disorders 50Funding top 13%Growth top 28%Talent top 38%Moat top 39% All 7 signals ▾Fundingtop 13% Growthtop 28% Talenttop 38% Moattop 39% Globalbottom 39% Marketbottom 33% Techbottom 32% Funding: Raised $305M across 7 rounds · 7 rounds over 6 yrs (1.2/yr) Growth: Headcount 20 → 27 (+35%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $305M | 11 mo ago | 27 | Chris Kroeger Founder & CEO | WordPress Block EditorElementorWordPress+22 | — | — |
| 6 | Merge Labs Developer of brain-computer interfaces to maximize human ability, agency, experience 48Talent top 28%Funding top 31%AI top 45%Patents top 49% All 8 signals ▾Talenttop 28% Fundingtop 31% AItop 45% Patentstop 49% Innovationbottom 49% Techbottom 45% Globalbottom 42% Marketbottom 31% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $250M | 5 mo ago | — | Sumner Norman Co-Founder | Apple iCloud MailGoogle WorkspaceNode.js+9 | 40 patents Real-time multi-user AR collaboration and interactive media streaming platforms | — |
| 7 | Autobahn Therapeutics Provider of therapeutics for CNS disorders by the regenerative medicine | $228M | 23 mo ago | 23 | Kevin Finney Chairman and CEO | — | — | — |
| 8 | Aspen Neuroscience Provider of genomic-based personalised pluripotent stem cell therapy 64Funding top 17%Patents top 23%Moat top 28%Innovation top 33% All 10 signals ▾Fundingtop 17% Patentstop 23% Moattop 28% Innovationtop 33% Growthtop 35% Newstop 45% Marketbottom 49% Talentbottom 49% Techbottom 46% Globalbottom 45% Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $224M | 6 mo ago | 94 | Damien Mcdevitt President | WordPress Block EditorWordPressMySQL+19 | 57 patents Patents concentrated in computing, sensing & instrumentation | — |
| 9 | Eledon Provider of therapeutics solution for organ or cellular transplantation in autoimmune and neurodegenerative… | $201M | 25 mo ago | 17 17 → 42 (+147%) · sector median +50% | — | DrupalApple iCloud MailMicrosoft 365+24 | — | — |
| 10 | Tenvie Developer of small molecule therapies for neurological, cardiometabolic, and ophthalmic diseases | $200M | 17 mo ago | — | Brian Cuneo Co-Founder & CLO | — | — | 4 job openings |
| 11 | Ventyx Biosciences Developer of therapeutics to treat autoimmune diseases | $165M | 20 mo ago | 79 | Raju Mohan Founder & CEO | DrupalPHPAmazon Web Services+18 | 54 patents TYK2 kinase inhibitor design, synthesis, and crystalline forms for immunomodulatory therapeutics | — |
| 12 | Cala Health Developer of a wearable non-invasive neuromodulation device 60Funding top 17%Product top 21%Innovation top 22%Patents top 26% All 11 signals ▾Fundingtop 17% Producttop 21% Innovationtop 22% Patentstop 26% Moattop 26% Talenttop 38% Techtop 46% Growthbottom 44% Marketbottom 43% Globalbottom 42% Newsbottom 21% Funding: Raised $157M across 7 rounds · 7 rounds over 13 yrs (0.5/yr) Product: 6 distinct product lines · Company stage: Series D rank vs industry peers · Fliar Intelligence Index 60/100 | $157M | 1 mo ago | 50 50 → 122 (+144%) · sector median +50% | Kate Rosenbluth Founder and Co-President | WordPressApple iCloud MailGoogle Workspace+31 | 243 patents Wearable peripheral nerve stimulation devices for tremor, movement and musculoskeletal disorder therapy | 1 award |
| 13 | Alto Neuroscience AI-driven drug discovery platform for neurological diseases based on patients biomarkers 72Funding top 12%Patents top 25%Growth top 30%Moat top 32% All 11 signals ▾Fundingtop 12% Patentstop 25% Growthtop 30% Moattop 32% Innovationtop 33% Techtop 45% AItop 45% Globalbottom 49% Talentbottom 49% Newsbottom 44% Marketbottom 40% Funding: Raised $145M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Patents: 57 patents matched (strict assignee match) · 57 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $145M | 3 mo ago | 34 | Amit Etkin Founder & CEO | BugHerdApple iCloud MailGoogle Workspace+15 | 57 patents Neuropsychiatric therapeutics: combinatorial dopaminergic/serotonergic drugs and EEG‑guided patient selection | 1 award |
| 14 | Nura Bio Provider of solution for diagnosis of a neurological disorder and neuroprotective medicines | $141M | 21 mo ago | 25 | Marc Freeman Co-Founder | — | — | — |
| 15 | Route 92 Medical Developer of next-generation products for neurointerventional procedures 69Funding top 14%Innovation top 18%Patents top 21%Moat top 29% All 10 signals ▾Fundingtop 14% Innovationtop 18% Patentstop 21% Moattop 29% Growthtop 32% Techtop 50% Talentbottom 49% Marketbottom 45% Newsbottom 41% Globalbottom 40% Funding: Raised $138M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) Innovation: 223 patents (top 12% of patent-holders) · 137 filings since 2022 vs 82 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $138M | 5 mo ago | 51 | Tony Chou Founder & CEO | WordPress Block EditorWordPressMySQL+23 | 223 patents Neurovascular aspiration catheters for minimally invasive stroke thrombectomy | — |
| 16 | Latigo Biotherapeutics Developer of non-opioid pain medicines for central nervous system | $135M | 16 mo ago | 17 | Nima Farzan Chief Executive Officer | — | 34 patents Voltage-gated sodium channel inhibitor drugs for pain and neurological therapies | — |
| 17 | Ambagon Developer of small-molecule therapeutics for the treatment of cancer | $103M | 16 mo ago | 49 | Luc Brunsveld Co-Founder | WordPressMySQLPHP+20 | — | — |
| 18 | Allay Therapeutics Developer of drugs for post-surgical pain management 42Funding top 18%Moat top 39%Market bottom 44%Global bottom 38% All 5 signals ▾Fundingtop 18% Moattop 39% Marketbottom 44% Globalbottom 38% Newsbottom 21% Funding: Raised $102M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 42/100 | $102M | 12 mo ago | 50 | — | — | — | — |
| 19 | Nudge Developer of whole-brain interfaces intended to improve human-brain interaction | $100M | 10 mo ago | — | Quintin Frerichs Co-Founder | Apple iCloud MailGoogle WorkspaceRadix UI+8 | 12 patents Automated, low-interaction glucose monitoring and insulin delivery systems for diabetes care | — |
| 20 | Openwater Provider of imaging technologies for medical diagnosis and treatments | $100M | 21 mo ago | — | Mary Lou Jepsen Founder & CEO | Wix eCommerceCart FunctionalityWix+17 | — | — |
| 21 | Octave Bioscience Provider of AI-based molecular diagnostic tools for neurodegenrative diseases 69Funding top 20%Innovation top 32%Growth top 35%Product top 35% All 11 signals ▾Fundingtop 20% Innovationtop 32% Growthtop 35% Producttop 35% Talenttop 38% Moattop 39% AItop 45% Techtop 48% Marketbottom 43% Newsbottom 42% Globalbottom 38% Funding: Raised $88.0M across 8 rounds · 8 rounds over 9 yrs (0.9/yr) Innovation: 2 product lines · Deep-tech classification: Tech Hardware rank vs industry peers · Fliar Intelligence Index 69/100 | $88M | 9 mo ago | 90 | William Hagstrom Co-Founder & CEO | WordPressApple iCloud MailGoogle Workspace+26 | — | 1 launch |
| 22 | Emboline Developer of an aortic embolic protection device 48Funding top 22%Moat top 26%Innovation top 28%Patents top 29% All 9 signals ▾Fundingtop 22% Moattop 26% Innovationtop 28% Patentstop 29% Talenttop 38% Techbottom 44% Newsbottom 42% Globalbottom 40% Marketbottom 28% Funding: Raised $81.9M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 112 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $82M | 3 mo ago | 13 13 → 23 (+77%) · sector median +50% | Amir Belson Founder & CTO | WordPressMySQLPHP+16 | 112 patents Embolic protection and delivery devices for cardiovascular catheter procedures | — |
| 23 | Therini Bio Limited information available | $62M | 13 mo ago | 13 13 → 15 (+15%) · sector median +50% | Daniel Burgess CEO | — | — | — |
| 24 | CuraSen Provider of therapeutics for neurodegenerative disorder | $60M | 21 mo ago | 16 | Mehrdad Shamloo Co-Founder | — | — | — |
| 25 | Noctrix Health Developer of wearable therapeutic device to treat neurological disorders | $57M | 9 mo ago | 8 | — | WordPressApple iCloud MailMySQL+16 | — | — |
| 26 | ReviR Therapeutics Developer of RNA-based therapeutics for multiple diseases 35Funding top 26%AI top 45%Moat top 47%Talent bottom 49% All 8 signals ▾Fundingtop 26% AItop 45% Moattop 47% Talentbottom 49% Marketbottom 36% Globalbottom 36% Techbottom 31% Newsbottom 18% Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) AI: Product described with: machine learning rank vs industry peers · Fliar Intelligence Index 35/100 | $54M | 1 mo ago | 29 | Yang Li Co-Founder | UbuntuElement UIVue.js+6 | — | 1 partnership |
| 27 | Titan Pharma A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | $38M | 11 mo ago | 11 | — | Apple iCloud MailMicrosoft 365Apache HTTP Server+8 | — | — |
| 28 | EicOsis Developing safer pain and inflammation treatments by restoring the body's natural healing | $31M | 14 mo ago | 14 14 → 7 (-50%) · sector median +50% | Robert Gregoire Co-Founder & CEO | — | 24 patents Solid-form pharmaceutical innovations for epoxide hydrolase and kinase inhibitor therapies | — |
| 29 | Neuro42 AI Provider of MRI and robotics technology for neurology | $30M | 9 mo ago | 34 | Abhita Vohra Co-Founder & CSO | WebflowSwiperjQuery+8 | 42 patents Low-field MRI hardware integration, AI‑enhanced image reconstruction, and electromagnetic interference mitigation. | — |
| 30 | Subsense Developer of non-surgical brain-computer interfaces using biocompatible nanoparticles | $27M | 6 mo ago | — | Tetiana Aleksandrova Founder & CEO | WordPress Block EditorWebflowWordPress+16 | — | — |
| 31 | OncoSynergy Developer of resistance mechanism inhibitors to treat cancer 11Funding top 28%Moat top 32%Patents bottom 48%Global bottom 42% All 6 signals ▾Fundingtop 28% Moattop 32% Patentsbottom 48% Globalbottom 42% Innovationbottom 33% Marketbottom 18% Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $27M | 1 mo ago | 3 | — | — | 26 patents Patents concentrated in chemistry & materials | — |
| 32 | Epalex Developer of therapies for treating neurological disorders | $26M | 7 mo ago | 2 | Brendan Magrab CEO | — | 30 patents Prodrug and formulation technologies for intravenous anesthetic propofol delivery | — |
| 33 | Magnus Medical Provider of non invasive neuromodulation system for depression treatment | $25M | 16 mo ago | 11 | Brandon Bentzley Co-Founder | Apple iCloud MailGoogle WorkspaceVue.js+8 | — | — |
| 34 | SiteOne Therapeutics Sodium ion channel 1.7 (Na 1.7) inhibitors for acute and chronic pain. | $24M | 13 mo ago | — | John Mulcahy Co-Founder & CEO | — | — | — |
| 35 | NeOnc Technologies Holdings Developer of a novel drug delivery platform for CNS diseases 53Funding top 30%Growth top 35%Innovation top 37%Talent top 38% All 8 signals ▾Fundingtop 30% Growthtop 35% Innovationtop 37% Talenttop 38% Techtop 42% Patentstop 42% Globalbottom 42% Marketbottom 25% Funding: Raised $22.3M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $22M | 4 mo ago | — | Thomas Chen Founder & Co-CEO | WordPress Block EditorElementorCart Functionality+26 | 48 patents Monoterpene-derived anticancer drugs, especially perillyl alcohol formulations for cancer therapy. | — |
| 36 | Aneuvo Developer of a medical device for the treatment of spinal cord injuries 32Growth top 35%Funding top 39%Tech top 49%Talent bottom 49% All 6 signals ▾Growthtop 35% Fundingtop 39% Techtop 49% Talentbottom 49% Marketbottom 25% Globalbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $22.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $22M | 3 mo ago | — | Yi Lo CEO | WordPressMySQLPHP+22 | — | — |
| 37 | SOLEY Therapeutics Developer of stem cell secreted factors for the treatment of myocardial infarction and stroke | $20M | 5 mo ago | 10 | Yerem Yeghiazarians Co-Founder & CEO | — | — | 1 job opening · 1 launch |
| 38 | Lighthouse Pharma Developer of therapeutics for neurology and infectious diseases 11Funding top 46%Talent bottom 49%Tech bottom 45%Global bottom 25% All 5 signals ▾Fundingtop 46% Talentbottom 49% Techbottom 45% Globalbottom 25% Marketbottom 18% Funding: Raised $15.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $15M | 1 mo ago | 4 | Casey Lynch Chief Executive Officer | WixSentryBootstrap+10 | — | 1 job opening |
| 39 | Novoron Bioscience Developer of therapeutics for neurological diseases 22Funding top 34%Innovation top 38%Product top 48%Global bottom 32% All 6 signals ▾Fundingtop 34% Innovationtop 38% Producttop 48% Globalbottom 32% Marketbottom 25% Techbottom 24% Funding: Raised $15.1M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Innovation: 3 product lines rank vs industry peers · Fliar Intelligence Index 22/100 | $15M | 3 mo ago | 11 11 → 16 (+45%) · sector median +50% | — | — | — | 1 job opening · 1 partnership |
| 40 | Navega Therapeutics Developer of gene therapy products for chronic pain management | $15M | 13 mo ago | 10 | Prashant Mali Co-Founder | — | — | — |
| 41 | SonALAsense Developer of therapeutic solutions for treating cancer, neurological disorders & others | $14M | 14 mo ago | 10 | Stuart Marcus Md Founder and Chief Scientific Officer | WixSentryBootstrap+12 | 22 patents Ultrasound‑enhanced drug delivery targeting tumor metabolism in low‑grade cancers | — |
| 42 | Neuronoff Developer of a neuromodulation device to restore and improve organ activity | $12M | 8 mo ago | 16 16 → 21 (+31%) · sector median +50% | Andrew Shoffstall Co-Founder | — | 48 patents Injectable flexible electrodes for minimally invasive neuromodulation and tissue ablation | — |
| 43 | Bloom Science Developer of therapies to treat neurological diseases | $12M | 14 mo ago | 26 | Christopher Reyes CEO | — | — | — |
| 44 | Cordance Medical Developer of a non-invasive medical device to open the blood-brain barrier | $9M | 6 mo ago | 9 | Bhaskar Ramamurthy Founder/CTO | — | — | — |
| 45 | Spinogenix Developer of therapeutics for brain injury and neurodegenerative diseases | $9M | 6 mo ago | 7 | Stella Sarraf Founder & CEO | WordPressMySQLPHP+20 | 58 patents Small-molecule spinogenesis promoters for ophthalmic, metabolic, and neurodegenerative therapies | 1 launch |
| 46 | SpineX Developer of a medical device for neurological conditions | $6M | 9 mo ago | 15 | — | WordPressMySQLPHP+23 | 5 patents Non‑invasive wearable CNS neuromodulation devices for spinal pain and motor disorder therapy | — |
| 47 | Elysium Therapeutics Developing innovative solutions to combat opioid overdose and reduce opioid abuse | $2M | 4 mo ago | 2 | Alex Sturmer President | — | — | — |
| 48 | Acumen Pharmaceuticals Developer of monoclonal antibody therapeutics for Alzheimer's disease | $2M | 3 mo ago | 52 52 → 67 (+29%) · sector median +50% | — | DrupalApple iCloud MailMicrosoft 365+22 | — | 1 partnership |
| 49 | Hillhurst Biopharmaceuticals Developer of carbon monoxide based therapeutics | $2M | 6 mo ago | — | Andrew Gomperts CEO & President | — | — | — |
| 50 | AcuraStem Developer of therapeutics for neurodegenerative diseases | $780K | 1 mo ago | 14 | Justin Ichida Co-Founder | — | 70 patents Antisense oligonucleotide therapeutics targeting SYF2, PIKfyve, UNC13A gene expression. | 1 expansion |
Top 12 Neurology companies in California
#1
Series E · Fremont, California · founded 2016 · 197 employees$680Mraised▾
Series E · Fremont, California · founded 2016 · 197 employees
Provider of implantable brain-computer interfaces. It offers flagship product the N1 Implant the Link which is a coin-sized device designed to decode neural signals and enable users to control digital devices using only their thoughts. It also has an experimental device called Blindsight to restore vision in individuals with optic nerve damage by directly stimulating the visual cortex.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Funding
top 15%Patents
top 25%Moat
top 25%Innovation
top 27%Talent
top 28%Market
top 33%Funding: Raised $680M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) · Last round Series E (May 2026)
Patents: 97 patents matched (strict assignee match) · 62 filings since 2022 vs 35 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 9/10 · IP moat: 97 patents · Unicorn
Audience (LinkedIn): 414k LinkedIn followers — 54.9% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2026Series E—
- May 2025Series E$650M
- Nov 2023Series D$43M
- Aug 2023Series D$323.2M
Founders & team
Investors
Founders Fund, Advaita Capital, Setcoin Group, MarketX, Ipo Club, Type One Ventures
Tech stack
Amazon AlbAmazon CloudfrontAmazon S3Amazon SesAmazon Web ServicesApple Icloud Mail
#2
Series D · Stanford, California · founded 2013 · 50 employees$157.1Mraised▾
Series D · Stanford, California · founded 2013 · 50 employees
Developer of a wearable non-invasive neuromodulation device. The company has developed a neuromodulation device that aims to provide relief of hand tremors in adults with essential tremors. It combines a watch-like device with an implantable sensor that externally stimulates peripheral nerves to reduce the same. The company has also developed a portable medical device with sensors to monitor the physical movement of a patient wearing or carrying the device.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 17%Product
top 21%Innovation
top 22%Patents
top 26%Moat
top 26%Talent
top 38%Funding: Raised $157M across 7 rounds · 7 rounds over 13 yrs (0.5/yr) · Last round Conventional Debt (Apr 2026)
Product: 6 distinct product lines · Company stage: Series D
Innovation: 243 patents (top 5% of patent-holders) · 127 filings since 2022 vs 106 in 2017-21 · 6 product lines
Audience (LinkedIn): 16k LinkedIn followers — 2.2% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Conventional Debt$50M
- Oct 2025Series D$50M
- Dec 2024Series D$50M
- May 2022Series D—
Founders & team
Investors
Google Ventures, Novartis, Johnson & Johnson Innovation, Baird Capital, Lux Capital, Lightstone Ventures
Tech stack
AccessibeAmplitudeApple Icloud MailCdnjsChoicesCloudflare
#3
Public · San Francisco, California · founded 2019 · 34 employees$144.7Mraised▾
Public · San Francisco, California · founded 2019 · 34 employees
AI-driven drug discovery platform for neurological diseases based on patients biomarkers. The company's platform measures patients biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to develop personalized psychiatric drugs. The company has pipeline of drugs including ALTO-100 for depression, ALTO-101 for neurodegenerative diseases, and more.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 12%Patents
top 25%Growth
top 30%Moat
top 32%Innovation
top 33%Tech
top 45%Funding: Raised $145M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Post IPO (Mar 2026)
Patents: 57 patents matched (strict assignee match) · 57 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Growth: Headcount 12 → 34 (+183%) across vintages · Fresh capital in last 24 mo
Audience (LinkedIn): 25k LinkedIn followers — 3.3% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Mar 2026Post IPO$120M
- Oct 2025Post IPO$50M
- Nov 2023Series C$45M
- Jan 2023Venture Debt—
Founders & team
Investors
Lightswitch Capital, Novartis, Sobrato, Alkeon Capital Management, Windham Venture Partners, What If Ventures
Tech stack
Apple Icloud MailAstraBugherdCloudflareCore-JsElementor
#4
Seed · San Francisco, California · founded 2025$250Mraised▾
Seed · San Francisco, California · founded 2025
Developer of brain-computer interfaces to maximize human ability, agency, experience. It focuses on creating new approaches to interact with the brain. The aim is to develop high-bandwidth brain-computer interfaces. These interfaces integrate with advanced artificial intelligence. The goal is to make the technology safe and accessible. The company seeks to restore lost abilities and support healthier brain states. It also aims to deepen connections and expand creative potential.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Talent
top 28%Funding
top 31%AI
top 45%Patents
top 49%Innovation
bottom 49%Tech
bottom 45%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Jan 2026)
AI: Product described with: artificial intelligence
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Jan 2026Seed$250M
Founders & team
Investors
OpenAI
Tech stack
Apple Icloud MailGodaddyGoogle WorkspaceHstsNext.JsNext.Js App Router
#5
Series F · San Mateo, California · founded 2015 · 51 employees$137.7Mraised▾
Series F · San Mateo, California · founded 2015 · 51 employees
Developer of next-generation products for neurointerventional procedures. The company's products include the FreeClimb Catheter Systems, which are advanced neurointervention systems to provide superior performance, and the Monopoint Reperfusion System to streamline delivery and enable super-bore aspiration at the most common stroke targets.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Funding
top 14%Innovation
top 18%Patents
top 21%Moat
top 29%Growth
top 32%Tech
top 50%Funding: Raised $138M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) · Last round Series F (Jan 2026)
Innovation: 223 patents (top 12% of patent-holders) · 137 filings since 2022 vs 82 in 2017-21 · Deep-tech classification: Tech Hardware
Patents: 223 patents matched (strict assignee match) · 137 filings since 2022 vs 82 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 12k LinkedIn followers
Funding rounds
- Jan 2026Series F$50M
- Jun 2024Series F$50.4M
- Nov 2023Series F$31.3M
- Dec 2021Conventional Debt$55M
Founders & team
Investors
InnovaHealth Partners, The Vertical Group, USVP, Norwest, Runway Growth Capital, Usventure
Tech stack
Backbone.JsBootstrapCloudflareCloudflare Bot ManagementCloudflare Browser InsightsContact Form 7
#6
Series D · Santa Cruz, California · founded 2011 · 13 employees$81.9Mraised▾
Series D · Santa Cruz, California · founded 2011 · 13 employees
Developer of an aortic embolic protection device. The Emboliner protects the brain and the rest of the body from embolic events (e.g., strokes) during cardiovascular procedures, especially catheter-based heart valve replacements. It is a Pro-Sheath device having a “sock-like” mesh filter that is deployed in the patient’s aorta at the beginning of the interventional procedure. The valve replacement surgery is conducted with the Pro-Sheath in place, providing embolic protection during the procedure.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 22%Moat
top 26%Innovation
top 28%Patents
top 29%Talent
top 38%Tech
bottom 44%Funding: Raised $81.9M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) · Last round Series D (Mar 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 112 patents · Soonicorn
Innovation: 112 patents (top 26% of patent-holders) · 50 filings since 2022 vs 38 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 995 LinkedIn followers
Funding rounds
- Mar 2026Series D$20M
- May 2021Series D$55.4M
- Jan 2021Series C$11.6M
- Jan 2020Series B$5M
Founders & team
Investors
Matrix Capital Management, ShangBay Capital, GAM, SV Tech Ventures, Trinity Capital, Western Technology Investment
Tech stack
Apache Http ServerCookiebotDiviGoogle AnalyticsGoogle Font ApiGoogle Tag Manager
#7
Series A · San Francisco, California · founded 2021 · 29 employees$54Mraised▾
Series A · San Francisco, California · founded 2021 · 29 employees
Developer of RNA-based therapeutics for multiple diseases. The company is leveraging machine learning technology and innovative RNA techniques to develop medicines for the treatment of cancer, rare genetic disorders, and infectious diseases.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%AI
top 45%Moat
top 47%Talent
bottom 49%Market
bottom 36%Global
bottom 36%Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series A (Apr 2026)
AI: Product described with: machine learning
Moat: Editorial + unicorn rating 3/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. CureCMT) announced in 12 mo
Funding rounds
- Apr 2026Series A—
- Nov 2025Grant (prize money)$4.6M
- Jul 2024Series A$30M
- Jan 2022Seed$20M
Founders & team
Investors
Lapam Capital, CDH, 5Y Capital, Yael Capital, Cmtrf, XtalPi
Tech stack
Core-JsElement UiGoogle WorkspaceLodashNginxSwiper
#8
Series C · San Diego, California · founded 2018 · 94 employees$224Mraised▾
Series C · San Diego, California · founded 2018 · 94 employees
Provider of genomic-based personalized pluripotent stem cell therapy. It offers regenerative cell treatment like dopaminergic neurons for Parkinson's disease and other neurological disorders. It maintains the genetic-based quality control to avoid the mutation of cells used for therapy.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 17%Patents
top 23%Moat
top 28%Innovation
top 33%Growth
top 35%News
top 45%Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Series C (Nov 2025)
Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 57 patents · Soonicorn
Audience (LinkedIn): 13k LinkedIn followers
Funding rounds
- Nov 2025Series C$115M
- Dec 2022Conventional Debt$40M
- May 2022Series B$147.5M
- Apr 2020Series A$70M
Founders & team
Investors
Orbimed, Arch Venture Partners, Frazier Healthcare Partners, Domain Associates, S32, Google Ventures
Tech stack
CloudflareCloudflare Bot ManagementCore-JsGeneratepressGeneratepress Gp PremiumGodaddy
#9
Series D · Redwood City, California · founded 2012 · 159 employees$617.6Mraised▾
Series D · Redwood City, California · founded 2012 · 159 employees
Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%News
top 24%Moat
top 31%Growth
top 43%Market
top 44%Talent
top 50%Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Jul 2025)
News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Leadership, Capital raise
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jul 2025Series D$320.8M
- May 2022Series C$430M
- Jun 2021Series B$100M
- May 2020Series A$87.6M
Founders & team
Investors
QVT Family Office, Dexcel, Foresite Capital, Narya, Amplo, Asia Alpha
Tech stack
CloudflareGoogle AnalyticsJqueryJquery MigrateModernizrMysql
#10
Acquired · San Francisco, California · founded 2011 · 3 employees$26.7Mraised▾
Acquired · San Francisco, California · founded 2011 · 3 employees
Developer of resistance mechanism inhibitors to treat cancer. It targets multiple hallmarks of cancer progression and have demonstrated efficacy as monotherapy and in strategic combinations. The lead drug program OS2966 therapeutic antibody blocking a cell surface receptor for the treatment of glioblastoma, ovarian, pancreatic cancer, and malignant meningioma.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 28%Moat
top 32%Patents
bottom 48%Global
bottom 42%Innovation
bottom 33%Market
bottom 18%Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents
Patents: 26 patents matched (strict assignee match) · 4 filings since 2022 vs 12 in 2017-21 · Latest publication 2023
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- May 2022Series A$3.5M
- Nov 2020Conventional Debt$250K
- Sep 2020Series A$3.2M
- Jan 2020Grant (prize money)$300K
Investors
National Cancer Institute, Connecticut Innovations, Navation, KICC, HHS, JLABS
#11
Public · Redwood City, California · founded 2018 · 27 employees$305Mraised▾
Public · Redwood City, California · founded 2018 · 27 employees
Developer of therapeutic for central nervous system disorders. The company's flagship product ML-004 helps in treating mental disorders, Alzheimer's agitation, and others. It has also developed ML-007, ML-009 for treating dyskinesia, schizophrenia, and ML-016 for treating anhedonia.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 13%Growth
top 28%Talent
top 38%Moat
top 39%Global
bottom 39%Market
bottom 33%Funding: Raised $305M across 7 rounds · 7 rounds over 6 yrs (1.2/yr) · Last round Series D (Jul 2025)
Growth: Headcount 20 → 27 (+35%) across vintages · Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 17k LinkedIn followers — 2.3% of this cohort's audience
Funding rounds
- Jul 2025Series D$372.5M
- Oct 2023Series C$225M
- Jul 2023Series C$50M
- Mar 2021Series B$30M
Founders & team
Investors
Novo Holdings, 5AM Ventures, Cowen, The Michael J. Fox Foundation, Forbion, Goldman Sachs
Tech stack
Animate.CssComplianzCore-JsDocusignElementorGenesis Blocks
#12
Seed · San Diego, California · founded 2013 · 11 employees$15.1Mraised▾
Seed · San Diego, California · founded 2013 · 11 employees
Developer of therapeutics for neurological diseases. It offer therapies for nerve regeneration in the central nervous system (CNS) specifically, spinal cord injury (SCI).It offer biologic therapeutics to inhibit the LRP1/Rho pathway and, thus, promote neuronal and axonal regeneration.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 34%Innovation
top 38%Product
top 48%Global
bottom 32%Market
bottom 25%Tech
bottom 24%Funding: Raised $15.1M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) · Last round Seed (Mar 2026)
Innovation: 3 product lines
Product: 3 distinct product lines · Company stage: Seed
Audience (LinkedIn): 2k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Sr. Research Associate / Scientist
Activity (LinkedIn): 1 partnerships (incl. Nelly Weiser and Colin Maraganore from Bija Ventures) announced in 12 mo
Funding rounds
- Mar 2026Seed—
- Feb 2025Grant (prize money)$844.7K
- Dec 2022Seed$12.1M
- Jan 2022Grant (prize money)—
Investors
NIA, Backstage Capital, Two Bear Capital, NIH SBIR/STTR, HHS, Bija Ventures
Tech stack
Cart FunctionalitySquarespace CommerceSquarespaceStimulusPriority HintsHsts
Funding & investor landscape
$14.1Btotal disclosed funding
276companies funded
934disclosed rounds
6rounds last 90 days
Most active investors
Y Combinator10 rounds
Notable founders
Dongjin Seo
Co-Founder · Neuralink
Elon Musk
Co-Foudner & CEO & Owner · Neuralink
Deanna Harshbarger
CEO · Cala Health
Kate Rosenbluth
Founder and Co-President · Cala Health
Amit Etkin
Founder & CEO · Alto Neuroscience
Sumner Norman
Co-Founder · Merge Labs
Sandro Herbig
Co-Founder · Merge Labs
Tony Chou
Founder & CEO · Route 92 Medical
Amir Belson
Founder & CTO · Emboline
Scott Russell
President and CEO · Emboline
Yang Li
Co-Founder · ReviR Therapeutics
Damien Mcdevitt
President · Aspen Neuroscience
Prism market signals · United States · country-scoped Prism corpus, 672,586 docs
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
RESEARCH IN CALIFORNIA · Health & Bio
How research on Neurotech in California is moving
A read on the academic research around Neurotech in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 761 papers.
UC San Francisco, UCLA, and USC lead California's neurotech research, predominantly advancing neurological disorder treatments and brain-computer interfaces with a cautiously optimistic tone.
761 papers · stance +0.40 · 23% breakthrough · 22% concern
top institutions
- University of California, San Francisco267
- University of California, Los Angeles126
- University of Southern California79
- University of California, Berkeley66
- California Institute of Technology60
leading researchers
Philip A. Starr · Jill L. Ostrem · Terence D. Sanger · Coralie de Hemptinne · Paul Larson · Nader Pouratian
prism intelligence · tone & topics
89% positive · 3% critical tone
HealthMedical ResearchNeuroscienceHealthcareMedicineMental Health
▲
Breakthroughs154 · 20%
▲ 17%→22% share
▲1.3× share momentum5 median citations53% since 2021mostly methods-led
Deep brain stimulation breakthroughs are surging — papers doubled from 16 to 33 while Neuromodulation jumped from 2 to 17.
rising sub-themes (early→recent)
- Deep brain stimulation16→33
- Neuromodulation2→17
- Neurostimulation3→16
- Stimulation6→17
- Sensory system2→6
Newly emergingEpilepsy 0→6 · GABAergic 0→3 · Globus pallidus 0→3
Landmark Gamma Oscillations in the Hyperkinetic State Detected with Chronic Human Brain Recordings in Parkinson's Disease · 325 cites
◆
Advancements368 · 48%
▼ 52%→47% share
▼0.9× share momentum10 median citations48% since 2021mostly empirical
Deep brain stimulation advancements intensifying — papers rose from 66 to 93, with Thalamus research newly scaling to 16.
rising sub-themes (early→recent)
- Deep brain stimulation66→93
- Stimulation21→47
- Neurostimulation17→31
- Thalamus3→16
- Neuromodulation7→19
Newly emergingTranscranial magnetic stimulation 0→10 · Anxiety 0→7 · Ictal 0→6
Landmark Dorsal and Ventral Attention Systems · 1,435 cites
▼
Concerns149 · 20%
▼ 21%→19% share
▼0.9× share momentum12 median citations48% since 2021mostly empirical
Safety concerns around Neurostimulation are rising sharply — papers grew from 2 to 12, with Chronic pain and Schizophrenia newly flagged.
rising sub-themes (early→recent)
- Stimulation1→15
- Neurostimulation2→12
- Deep brain stimulation35→42
- Neuroscience14→21
- Neuromodulation2→8
Newly emergingChronic pain 0→4 · Mood 0→3 · Schizophrenia (object-oriented programming) 0→3
Landmark Current and future directions of deep brain stimulation for neurological and psychiatric disorders · 291 cites
Common questions
How many Neurology companies are there in California, United States?
Radar tracks 441 indexable Neurology companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Neurology companies in California, United States?
The Neurology companies in California, United States on this list have raised a combined $14.1B in disclosed equity funding across 276 funded companies.
Which is the highest-funded Neurology company in California, United States?
Biosplice is the highest-funded Neurology company in California, United States, with $778M in disclosed equity funding.
How many Neurology companies in California, United States are funded?
276 of the 441 Neurology companies in California, United States on this list have disclosed at least one equity funding round.
How many Neurology unicorns are there in California, United States?
3 Neurology companies in California, United States on this list are valued at $1B or more.
Who are the top investors in California, United States Neurology companies?
The most active investors in California, United States Neurology companies on this list include HHS, NIH, JLABS, Orbimed, The Michael J. Fox Foundation.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.